Browse Articles

Discover research articles across all indexed journals

Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC).

Journal of Clinical Oncology Priyanka Vinod Chablani, Ali Raza Khaki, Karine Tawagi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.770

770 Background: EVP is a preferred 1st-line option for patients (pts) with la/m UC. We sought to understand how genitourinary (GU) medical oncologists in the US treat pts who progress on 1L EVP, and their comfort level with immune checkpoint inhibitor (ICI) rechallenge after prior ICI exposure. Methods: We convened a bladder cancer working group comprised of 11 expert la/m UC GU oncologists. This group created an 11-question survey addressing key questions regarding treatment sequencing, including treatment after 1L EVP. The survey was e-mailed to 227 US GU oncologists from May - Aug 2024. GU oncologists in the Bladder Cancer Advocacy Network and those with a known GU-focus in academic and community practices were selected. Here, we present results regarding 2L treatment after 1L EVP, using descriptive statistics. Results: We received 78/227 responses (34%); 72% report seeing > 25 pts with la/m UC/yr, 21% see 11-25 pts/yr. 71 oncologists completed the 2L treatment question. After progression on EVP, 77% (55/71) were somewhat/very likely to give platinum-based chemotherapy (PBC), 80% (57/71) would not include nivolumab with gemcitabine + cisplatin in the 2L, and 62% (44/71) were somewhat/very unlikely to give switch maintenance ICI after 2L PBC (Table). For other 2L options, 87% (62/71) were somewhat/very likely to give erdafitinib in pts with FGFR3 alterations (alt), and 56% (40/71) were somewhat/very likely to give sacituzumab govitecan (SG). SG use before and after TROPiCS-04 trial press release on 5/30/24 shifted from 63% (24/38) to 48% (16/33) somewhat/very likely to use SG (and 21% [8/38] to 39% [13/33] somewhat/very unlikely to use). Regarding clinical trials after 1L EVP, 80% (57/71) were somewhat/very likely to recommend a non -ICI containing trial. Conclusions: After progression on EVP, most GU oncologists favor PBC without combination ICI, PBC without ICI switch maintenance, or erdafitinib (in FGFR3-alt) as 2L therapies. For clinical trials 2L, more oncologists favor a non -ICI containing regimen. Additional data, including the impact of residual toxicity from 1L EVP on 2L treatment selection, and treatment of pts with HER-2 IHC3+ tumors, are needed to better understand treatment sequencing for pts with la/m UC. At the time of survey build, trastuzumab deruxtecan had recently received pan-tumor approval. Limitations include selection bias and lack of clinical outcomes. 2L Treatment after EVP Somewhat or very likely to use, % (n) Somewhat or very unlikely to use, % (n) Gemcitabine + Cisplatin + Nivolumab 11 (8) 80 (57) PBC with switch maintenance ICI 31 (22) 62 (44) PBC without switch maintenance ICI 77 (55) 13 (9) Erdafitinib for FGFR3 -alt 87 (62) 7 (5) SG 56 (40) 30 (21) ICI-combo trial 54 (38) 35 (25) Non-ICI trial 80 (57) 8 (6) Continue EVP for progression in 1-2 sites after using local therapy (e.g. radiation) 83 (59) 8 (6)

Anisotropic phonon responses of 2D NbOX2 (X<b>=</b>Cl, Br, I) under uniaxial tensile strain

Applied Physics Letters Xiaoyue Fan, Ziling Shen, Deng Hu et al. Feb 10, 2025 DOI: 10.1063/5.0253382

The van der Waals crystal NbOX2 (X = Cl, Br, I) has recently attracted much attention due to its remarkable in-plane anisotropy and substantial second-order nonlinear optical response. Moreover, the importance of modulating its physical properties through strain has become increasingly prominent. Herein, we investigate the anisotropic phonon response of NbOX2 along various crystallographic directions under uniaxial tensile strain by Raman spectroscopy. The results show that opposing frequency shifts manifest in the Raman modes when uniaxial tensile strain is applied either parallel or perpendicular to the polar axis, and the highest frequency peak, P5, shows significant blue or red shifts. Density functional theory calculation results are consistent with the observed Raman shifts under strain. The change in Nb–O bond length is the main reason for the significant blue shift of P5. The anisotropic and pronounced frequency shifts of NbOX2 under strain can serve as sensitive indicators for strain modulation, offering insights for potential applications such as flexible optoelectronic devices and strain sensors.

User experience with pregnancy tracker mobile apps: Findings from comment-based qualitative study

PLoS ONE Md. Alamgir Hossain, Janet Perkins, Md Tanvir Hasan et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0318012

Background Worldwide, millions of pregnant women use pregnancy-related apps to monitor their baby’s growth and development. While most of the apps are user-friendly, not all of them are equally appealing. This study aimed to explore the user experience (UX) of pregnancy tracker mobile apps used by pregnant women. Methods This study explored the dynamics between users’ experiences and multifaceted dimensions of advanced features, high-quality materials and information, strict privacy policies, problem-solving abilities, and the usefulness of app features and contents. This study applied reviewers’ comment-based qualitative study, accessing crowdsourced data gathered from different pregnancy tracker app websites. A thematic and content analysis approach was used. Results This study found that when users are satisfied with using advanced content and features, it aligns with their perceived self-righteousness and rationality, and reflects their cultural values and expectations of using the apps. Conversely, when users encounter challenges such as erroneous baby size comparison and app updating issues, they perceive these as disadvantages of the apps utilised. Moreover, the study sheds light on the specific desires of pregnant women, highlighting their expectations for content that addresses their physical and mental well-being, as well as their unborn babies. The desire for free access reflects the cultural emphasis on cost-effectiveness, while the willingness to invest financially in enhanced experiences demonstrates the recognition of the value and potential benefits of improved content and features. This study also provides valuable insights into the complex relationship between users’ experiences, cultural values, advanced features, high-quality materials and information, privacy policies, problem-solving abilities, and relevant content in creating positive app experiences that align with users’ cultural expectations and needs. Conclusion This study provides essential insights into the user experience and underscores the importance of a user-centric design approach for developers. By capturing the current landscape of these digital tools, can provide valuable feedback for the enhancement of existing applications and guide the development of future iterations, ensuring the diverse preferences and expectations of pregnant women worldwide.

Study on molecular mechanism of polyoxyethylene to prevent coal and rock and gas composite dynamic disasters

Scientific Reports Xuyang Bai, Junwen Zhang, HaiXiang Guo et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89634-5

Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial.

Journal of Clinical Oncology Alan Pollack, Marla Johnson, James Proudfoot et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.399

399 Background: The three-arm randomized SPPORT trial (n=1792) examined the effect of treatment intensification on the outcome of men treated with salvage radiotherapy (RT) for a detectable PSA. The arms were prostate bed RT (PBRT) alone (Arm I), PBRT + short term androgen deprivation therapy (STADT; Arm 2), and PBRT + STADT + pelvic lymph node RT (PLNRT; Arm 3). With treatment intensification in Arms 2 and 3, there were significant incremental gains in the primary freedom from progression (FFP) endpoint, but not metastasis free survival (MFS) with about 8 yr median follow-up; although metastatic events were reduced with intensification. Decipher score (DS) is strongly prognostic for metastasis and was hypothesized to be independently significant of clinical-pathologic covariates in predicting the need for treatment intensification. The main objective was to determine if gene expression estimates of metastatic risk using Decipher score result in significant interactions with treatment, especially for PLNRT. Methods: Prospectively collected prostatectomy tissuewas available for RNA extraction and generation of DS (Veracyte, San Diego, CA) in 916 patients. The protocol FFP endpoint included biochemical (nadir+2 ng/mL) failure, clinical failure, or death from any cause. MFS included distant metastasis or death from any cause. Multivariable (MVA) Cox models adjusted for Gleason score, margin status, pT-stage, pre-RT PSA, age, and race. Results: DS (median 0.61; IQR: 0.45-0.79) were obtained for 709 patients (median follow-up 7.9 yr), with 215 in Arm 1, 247 in Arm 2, and 247 in Arm 3. The arms were balanced for key covariates. There were 226 FFP and 136 MFS events. On MVA, DS (per 0.1 unit) was prognostic for FFP (HR 1.10, 95% CI 1.03-1.17, p=0.007) and borderline for MFS (HR 1.08, 95% CI 0.99 - 1.18, p=0.08). There was no significant DS-related benefit to adding STADT to PBRT. Adding PLNRT + STADT to PBRT resulted in a greater benefit in patients with high (&gt;0.60, HR 0.36, 95% CI 0.25-0.54, p&lt;0.001) vs. lower (≤0.60, HR 0.76, 95% CI 0.46-1.26, p=0.29) DSs, with an absolute benefit of 27% vs. 11% in high vs. lower DS, along with a significant treatment interaction on MVA (p-int = 0.04). Relative MFS benefit from adding PLNRT + STADT to PBRT ± STADT was greater in patients with high (HR 0.60, 95% CI 0.37-0.97, p=0.04) vs. lower (HR 1.14, 95% CI 0.66-1.98, p=0.63) DS, with a 10-year absolute benefit of 6% vs. 0%, and a borderline significant treatment interaction on MVA (p-int = 0.06). Conclusions: The unique SPPORT trial intensification design facilitated the discovery that high metastatic risk, as assessed by DS, may be abrogated at least in part by PLNRT, suggesting that lymph node micrometastases are a sole site of metastasis in some patients. Decipher score is a meaningful predictor of gains from PLNRT. Clinical trial information: NCT00567580 .

Understanding incidence and outcomes of testicular and ovarian germ cell tumors from 2000–2017 using population-based cancer registries.

Journal of Clinical Oncology Domenique Escobar, Irene Chen, Lihua Liu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.649

649 Background: Both testicular (TGCT) and ovarian germ cell tumors (OGCT) originate from a common primordial germ cell lineage prior to differentiation into sperm or eggs and share several features. While TGCT are extensively studied, less is known about OGCT but given the relative rarity of both TGCT and OGCT, we aimed to comprehensively assess the current landscape of these diseases using population-based cancer registries that surveil the entire civilian population of the US. Importantly, this analysis includes all data from 2000 to 2017 and is therefore not subject to the impacts on cancer data reporting during the COVID-19 pandemic in the US. Methods: We accessed population-based data available from the year 2000 forward from Surveillance, Epidemiology, and End Results (SEER) and National Program of Cancer Registries (NPCR) registry networks to obtain information about incidence and outcomes of TGCT and OGCT. NPCR+SEER was utilized to characterize nation-wide patterns of incidence according to demographic features and histologic type, SEER21 to describe age-specific patterns, SEER18 to describe outcomes and SEER9 to describe long-term patterns of age-specific incidence according to year of diagnosis and year of birth. Detailed descriptive analysis were performed. Age-adjusted incidence rates (AAIRs) and temporal trends were calculated overall and stratified by race/ethnicity and histology. Observed and relative survival were also assessed overall and according to race/ethnicity and histology. Results: TGCTs were far more common than OGCTs and the majority of all GCTs occurred in adolescents and young adults. The AAIRs of TGCT were greatest in NH white men and for OGCT, greatest in Hispanic White women. Seminoma was the most common histology in TGCT, and dysgerminoma was most common in OGCT. For TGCT, the most drastic increases in incidence were noted in Hispanic and American Indian/Alaska Native men, whereas incidence was relatively stable in non-Hispanic white men. For OGCT, incidence was relatively similar amongst racial/ethnic groups. We also found that observed survival in Black men with TGCT is worse than all other racial/ethnic groups, but relative survival is comparable. A similar and more pronounced finding was seen in OGCT, but Black women experienced both worse observed and relative survival compared to the other groups. Regarding histology, those with seminoma or dysgerminoma had better survival than those with NSGCT/non-dysgerminoma. Conclusions: We present a contemporary and comprehensive assessment of incidence and outcomes of TGCT and OGCT for the entire US civilian population from 2000-2017, that is not subject to impacts of cancer reporting during the COVID-19 pandemic. We identified various racial/ethnic differences in incidence and survival both within and between TGCT and OGCT, which highlights opportunities to intervene.

Outcomes of immune-checkpoint inhibitor rechallenge in urothelial carcinoma: Results from a global real-world evidence study.

Journal of Clinical Oncology Brigida Anna Maiorano, Antonio Cigliola, Valentina Tateo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.732

732 Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of urothelial carcinoma (UC) across clinical stages. Several ICIs have been approved by regulatory agencies for both adjuvant and metastatic settings. Limited information is available regarding the efficacy of rechallenge with ICI following progression on prior ICI-based therapy. We hypothesized that ICI rechallenge could be effective in selected pts with UC. Methods: A retrospective study was performed using the TriNetX analytics platforms for a large-scale search of patients (pts) with UC who underwent 2 lines of ICI (± other treatments between ICIs, either alone or in combo with other agents) at healthcare organizations collaborating through a TriNetX-mediated network across international sites. Descriptive statistics were used to summarize the clinical and demographic characteristics of pts. Kaplan-Meier analysis was used to estimate progression-free and overall survival (PFS, OS) with ICI rechallenge. Data were analyzed in October 2024. Results: From a total of 35,789 pts with UC, a cohort of 267 pts, treated with 2 sequential ICIs between 2014 and 2024, was identified (195M, 71F). The baseline median age was 73 years. Overall, 86% had bladder vs. 14% upper tract primary tumor. At initial diagnosis, 27% had stage IV, while 73% had stage I-III disease; 19% of pts had undergone radical cystectomy. 12% of pts were reported to have FGFR3 alterations, 12% PD-L1 positive. The median time on prior ICI was 19.5 months (mos - range: 16-27.5). The median time from the end of ICI to the start of ICI rechallenge was 6.4 mos. The most common ICI sequence was nivolumab followed by pembrolizumab (28.5%), then avelumab followed by pembrolizumab (22.4%), atezolizumab followed by pembrolizumab (20.8%), pembrolizumab followed by nivolumab (14.9%), pembrolizumab followed by avelumab (13.4%). The longest median (m)PFS was observed with anti-PD1 after anti-PD-L1 therapy (11.1 mos, range 0.89-38.4). The efficacy of ICI rechallenge was independent of the setting of prior ICI: perioperative vs. metastatic stage (p=0.16). mPFS with ICI rechallenge was 10.3 mos in pts treated with ICI ³12mos after the end of their prior ICI vs 6.0 mos in those rechallenged within &lt;12mos (p=0.15); mPFS was 9.0 mos in pts treated with ICI ³6mos after the end of prior ICI vs. 3.4 mos in those rechallenged within &lt;6mos (p=0.19). After a median follow-up of 22.7 mos, the mOS of ICI rechallenge was 25.8 mos. Conclusions: Although it is an uncommon strategy, ICI rechallenge after prior ICI-based therapy may benefit a subset of pts with UC, with outcomes varying based on the specific ICI regimen. Limitations include retrospective nature, variability in the timing of imaging across practices, and potential selection and confounding biases.

Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis

Journal of Clinical Oncology Eric M. Jurgens, Ross S. Firestone, Jagrutiben Chaudhari et al. Feb 10, 2025 DOI: 10.1200/jco-24-01785

MCARH109 is a first-in-class G protein–coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. This phase I clinical trial included 17 patients and determined that MCARH109 is safe at a maximum tolerated dose of 150 × 10 6 CAR T cells. In this updated analysis, no new serious adverse events were reported at a median follow-up of 37 months. Overall, 12 (71%) of 17 patients responded, including seven (70%) of 10 patients previously treated with B-cell maturation antigen-targeted therapy. The median duration of response was 8.6 months (95% CI, 5.7 to not reached [NR]) with two patients sustaining a stringent complete response at the time of last follow-up, 32 months and 41 months, respectively. The median overall survival (OS) was NR and the 3-year OS estimate was 59% (95% CI, 40 to 88). Possible GPRC5D loss via immunohistochemistry was observed in 6 (60%) of 10 patients at relapse. High-dimensional spectral cytometry–based immune profiling associated an activated T-cell phenotype at apheresis with a response to MCARH109.

Oxygen vacancy distribution and phase composition in scaled, Hf0.5Zr0.5O2-based ferroelectric capacitors

Applied Physics Letters T. Iung, L. Pérez Ramírez, A. Gloskovskii et al. Feb 10, 2025 DOI: 10.1063/5.0245595

In this paper, we address correlations between film thickness, phase composition, and oxygen vacancy (VO) distribution in scaled, hafnia-based ferroelectric capacitors (FeCAPs), necessary to achieve low operating voltages, higher endurance, and advanced node integration. Using x-ray photoelectron spectroscopy, hard x-ray photoelectron spectroscopy, grazing incidence x-ray diffraction, and electrical characterization, we investigate the evolution of phase composition and VO profiles in Hf0.5Zr0.5O2 (HZO) films of 6 and 10 nm thickness. We demonstrate that thinner films exhibit a greater fraction of the non-polar tetragonal phase (t-phase), with increased VO concentration at the interface, affecting the device performance. Electrical measurements reveal contrasting wake-up and fatigue behavior between the two thicknesses, with thinner films showing decreased remanent polarization (2PR) due to t-phase dominance and VO redistribution during field cycling. These findings highlight the critical interplay of strain, phase stability, and VO dynamics, providing key insights for the optimization of HZO-based FeCAPs for advanced, low-power memory applications.

The effects of L-carnitine and fructose in improved Ham’s F10 on sperm culture in idiopathic severe asthenospermia within 24h

PLoS ONE Dehui Chang, Fudong Li, Yindong Kang et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0306235

To study the effects of L-carnitine and fructose on semen parameters of severe asthenospermia patients by sperm culturing in vitro within 24h. We optimized the energy composition and antioxidant substances of sperm culture medium in vitro (based on Ham’s F10 culture medium) by orthogonal test for preparing high quality culture medium. Sperms of 60 patients with idiopathic severe asthenospermia were collected, and cultured in vitro within 24h, by Ham’s F10 culture medium added to different concentrations of L-carnitine and fructose and culture temperature, whose effects on sperm motility were observed to determine which is the most appropriate concentration and temperature. For determining the appropriate concentration of L-carnitine and fructose and the suitable culture temperature in Ham’s F10 culture medium, the orthogonal experiments were carried out to optimize above three factors, which had great influence on sperm viability, survival rate, deformity rate and DNA fragmentation index (DFI). The final concentration of L-carnitine and fructose was determined in terms of initial tests to assess the effects of different concentrations (4, 8, 12, and 16 mg/ml L-carnitine and 0.125, 0.250, 0.375, and 0.50 mg/ml fructose) on sperm viability and motility in culture. During the operation of processing and culturing sperms in vitro within 24h, orthogonal test showed that sperm viability was better at the final concentration of 8 mg/ml L-carnitine and 0.375 mg/ml fructose in improved Ham’s F10 culture medium at 36.5°C. Idiopathic severe asthenospermia sperm can be effectively improved by the modified Ham’s F10 culture medium of the final concentration of 8 mg/ml L-carnitine and 0.375 mg/ml fructose at 36.5°C within 24h, which has shown better culture effect and is superior to Ham’s F10 basic medium.

Comparative analysis of fungal and bacterial composition in natural wines and their closest pesticide-treated counterparts

Scientific Reports Robin Mesnage, Jérôme Douzelet, Gilles-Eric Seralini Feb 10, 2025 DOI: 10.1038/s41598-025-88655-4

Assess the journey: Characterizing muscle-invasive bladder cancer patients who receive neoadjuvant therapy and do not proceed with cystectomy.

Journal of Clinical Oncology Jay Ogunkeye, Ruth E Belay, Eila C. Skinner Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.746

746 Background: The standard treatment of muscle invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC), offering a 5-10% survival benefit and reducing recurrence by 35%. However, little is known about the patients who start NAC but do not proceed to RC. In the SWOG-8710 trial, 18% of patients did not undergo surgery after NAC. Platinum-based regimens, while generally well tolerated, sometimes cause severe side effects. With increasing NAC use and evolving treatment options, some patients start NAC without completing definitive treatment. This study aims characterize patients who do not proceed with RC, focusing on their NAC experience and alternative treatments. Methods: A retrospective analysis was performed on MIBC patients recommended for neoadjuvant therapy followed by RC between 2020-2023 by a single provider at Stanford Health Care. Eligible patients had clinically localized bladder cancer (cT2-T4N0) who initiated neoadjuvant therapy and were deemed surgical candidates. Patients who were not platinum-eligible received alternative therapies on clinical trials . Data were collected on patient demographics, comorbidities, functional status, renal and hematologic function, and NAC administration. Patients who underwent cystectomy were excluded. Results: A total of 90 patients with MIBC who had a treatment plan involving neoadjuvant therapy followed by RC between 2020-2023 were identified. 22% (20/90) of these patients did not undergo cystectomy. The median age was 76, 75% male, 75% white. 50% of patients had variant or non-urothelial carcinoma histology. 60% were cT2 at time of initial consult. The majority of patients (80%) received platinum-based NAC, with only 4 receiving alternative therapies. One patient died of a stroke before completing NAC. The reasons for not undergoing RC were declining additional treatment (30%) and inability to tolerate surgery due to toxicity from therapy (30%), followed by patient preference of radiation therapy (20%), and disease progression (10%). Two additional patients were taken to the operating room; however, surgery was aborted due to unresectable disease and anesthetic complications. Among those who did not undergo RC, 42% opted for surveillance, 37% received trimodal therapy (TMT), and 21% received additional immunotherapy. Conclusions: In this study, we were able to gain a better understanding of our patient cohort who started neoadjuvant therapy but did not proceed to cystectomy. Reasons for this decision included toxicity related to neoadjuvant therapy, personal desire to forgo surgery, or prioritization of bladder preservation. These findings highlight the need for future efforts aimed at trying to predict this patient population and further comparative analysis of outcomes between this cohort and those who underwent cystectomy.

Prevalence of germline variants of uncertain significance in DNA repair genes and their potential impact on prostate cancer outcomes following radical prostatectomy.

Journal of Clinical Oncology Giuseppe Chiarelli, Vittorio Fasulo, NicolòMaria Buffi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.421

421 Background: Pathogenic variants (PVs) in DNA repair genes (DRG) are linked to a higher risk of aggressive prostate cancer (PCa). Understanding and managing variants of uncertain significance (VUS), however, remains a challenge. This study investigates the prevalence of germline VUS in PCa patients and their potential link to prognosis following robot-assisted radical prostatectomy (RARP), aiming to enhance clinical management and risk stratification. Methods: This is part of an ongoing PCa screening project in the Italian population aimed at identifying men with a genetic predisposition (AIRC - Fondazione AIRC per la Ricerca sul Cancro, IG 2020 ID 25027). Germline DRG variants were identified in men with high-risk PCa or those aged &lt;50 scheduled for RARP. After informed consent, blood samples were collected, and data on age, stage, PSA, ISUP grade, and family history were recorded. Genetic analysis used a multigene panel, classifying VUS and PVs per ACMG/AMP and IARC guidelines. Primary outcome: VUS prevalence; secondary: correlations between VUS and pathological status, biochemical recurrence (BCR), and need for adjuvant therapy. Results: A total of 138 men who underwent RARP were enrolled. The median age was 64 years (IQR 57–68). ISUP grade was 1–2 in 54.0% of patients and 3–5 in 46.0%. Family history of PCa was present in 55%. Median PSA was 7.5 ng/mL (IQR 3.3–9.4). DRG variants were identified in 41 men (29.7%), of whom 34 (82.9%) had VUS and 7 (17.1%) had PVs (3 BRCA2, 1 BRCA1, 2 PALB2, 1 CHEK2). VUS carriers were younger at diagnosis (median 62 vs. 64 years). 25.8% of VUS carriers were node-positive, compared to 13.5% of those with negative DRG (p &gt; 0.05). BCR occurred in 24% of VUS patients vs. 18% of those without DRG variants at nearly 2.5 years of follow-up, but this difference was not statistically significant. No significant differences in ISUP grade or positive margin rates were observed. Conclusions: VUS germline mutations are common in PCa patients undergoing RARP. These mutations appear associated with worse outcomes. Study limitations include a single-center cohort, small sample size, and a predominantly European ancestry population.

Validation of navigator-assisted hypofractionation (NAVAH) program surveys in African-American prostate cancer patients.

Journal of Clinical Oncology Erica Fleming Hall, Ursula Burnette, Tamika Smith et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.313

313 Background: Prostate cancer is a leading cause of malignancy and death in men. African-Americans have the highest overall cancer death rate and shortest survival time of any racial or ethnic group in the United States, with African-American prostate cancer patients having a morality rate 80% higher than White patients. The disparities in access to radiation therapy (RT), mortality rates, and treatment outcomes among African-American prostate cancer patients compared to other populations highlight the urgent need for targeted interventions. The Navigator-Assisted Hypofractionation (NAVAH) program, with its innovative patient navigation approach and culturally sensitive survey, aims to better identify the specific barriers faced by African-American patients with prostate cancer. This study is a report of the NAVAH program experience piloting a culturally sensitive survey in African -American prostate cancer patients. Methods: African-American patients with established prostate cancer having seen a Radiation Oncologist and consented to receive RT were recruited to participate in our ongoing Phase I trial (clinicaltrials.gov, NCT05978232); those enrolling on trial were administered surveys prior to receipt of RT. Survey information was assessed by topic category and survey responses were combined into a representative score for each category (outstanding, excellent, good, average, below average). Survey categories include availability (access to a medical center, coordinating care, and overall quality of care), accessibility (transportation, distance to care, and healthcare literacy), affordability (financial considerations, employment, and level of education), accommodation (access to internet, navigating transportation), acceptability (comfort and prejudice among interactions with the system), and cancer screening/cancer treatment. Results: Mean scores noted good availability (32 responses), excellent accessibility (20 responses), excellent affordability (22 responses), excellent accommodation (18 responses), average acceptability (44 responses), and average cancer screening/cancer treatment (40 responses). Patients noted neutral to positive interactions with doctors and nurses, but distrust of following the advice given to them at hospitals, and that the time interval from their first abnormal test to being informed of a cancer diagnosis was too long. Conclusions: Our findings indicate that this novel survey design is feasible in the African-American prostate cancer population. As more patients enroll in our ongoing Phase I trial, implementation of this survey will provide more definitive and comprehensive answers regarding additional topics, including financial challenges during treatment, access to accommodations, and perception of treatment during cancer care.

Impact of renal cell cancer histology on outcomes of microscopic positive surgical margins and implications on post-surgical follow-up.

Journal of Clinical Oncology Margaret F. Meagher, Giacomo Musso, Dhruv Puri et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.519

519 Background: Positive surgical margins (PSM) are associated with worsened survival outcomes in Renal Cell Carcinoma (RCC). Current AUA guidelines recommend intensified post-surgical follow-up and clinical vigilance in patients with PSM. We sought to evaluate outcomes of different RCC-histologies with microscopic-PSM. Methods: We performed a retrospective analysis of patients undergoing partial nephrectomy (PN) or radical nephrectomy (RN) for RCC who had microscopic-PSM. The cohort was divided according to RCC-Histology [Chromophobe-RCC (chRCC); Clear Cell-RCC (ccRCC); Papillary-RCC (pRCC) for descriptive and survival analyses. Primary outcome was all-cause mortality (ACM)/overall survival (OS). Secondary outcome was cancer-specific mortality (CSM)/cancer-specific survival (CSS). Cox proportional hazards multivariable analysis (MVA) was used to elucidate predictive factors for ACM and CSM. Kaplan-Meier Analysis (KMA) was performed to analyze 5-year OSS and CSS. Results: A total of 8100 patients were analyzed, and we identified 312 patients with microscopic-PSM [26 (8.3%), 236 (75.6%), and 50 (16.0%) of patients had chRCC, ccRCC, and pRCC respectively]. Cox-regression revealed ccRCC to be associated with worsened ACM (versus chRCC [referent] HR=7.8, p=0.042), and worsened CSM (versus chRCC [referent] HR=2.97, p=0.033); pRCC did not demonstrate worsened ACM (p=0.148) and CSM (p=0.201). Comparing chRCC, ccRCC, and pRCC, KMA revealed a 5-year OS of 91%, 87%, and 63%, (p=0.024) and 5-year CSS of 93%, 86%, and 65%. KMA comparing microscopic-PSM versus negative surgical margins (NSM) noted no significant difference in 5-year OS for chRCC (85% vs. 86%, p=0.365) or pRCC (80% vs. 84%, p=0.952), but significantly lower 5-year OS in microscopic-PSM in ccRCC (77% vs. 85%, p&lt;0.001). Conclusions: In patients with microscopic-PSM, we noted significant differences according to histology, with ccRCC being associated with significantly worsened survival and mortality outcomes when compared to chRCC and pRCC; microscopic-PSM was also associated with significantly worsened survival compared to NSM in ccRCC, but not chRCC and pRCC. Microscopic-PSM can be considered to represent a higher risk subgroup in ccRCC but not chRCC or pRCC. Intensified post-surgical follow up compared to NSM patient is appropriate in ccRCC, while microscopic-PSM in chRCC and pRCC can be followed similarly to NSM patients with the same histology.

Li-ion storage characteristics and migration mechanisms of intrinsic, doped, and oxygen-deficient CeO2 and La2O3: A study using DFT+<i>U</i>

Applied Physics Letters Yucheng Hu, Na Jin, Lei Sun et al. Feb 10, 2025 DOI: 10.1063/5.0251743

Rare-earth oxides (REOs) represented by CeO2 and La2O3 became a focal point in the study of Li-ion battery (LIB) electrode materials. However, leveraging defects to tune the intrinsic electronic structure of REO to enhance electrochemical performance, as well as understanding the underlying physical mechanisms at the atomic level, remained an open challenge. Density functional theory plus U calculations revealed that doping and oxygen vacancies not only regulated Li-ion insertion stability but also reduced the migration energy barriers in CeO2. Doping also decreased the volume change rate of CeO2 during Li-ion insertion. Oxygen vacancies lowered the Li-ion migration energy barrier in CeO2 from 1.516 to 0.903 eV. In comparison, Li-ion migration energy barriers in the La2O3 series structures were significantly lower than those in CeO2. Experimental results confirmed that the Li-ion diffusion coefficient of La2O3 was markedly higher than that of CeO2. Upon Li-ion insertion, the bandgap of CeO2 decreased from 2.18 to 1.60 eV, and density of states analysis revealed the profound impact of lithiation on the electronic structure. This comprehensive study enhances the understanding of the application potential of these typical rare-earth oxide materials in LIBs.

The effects of flight training on flying cadets’ brain structure

PLoS ONE Liang Wang, Chengshi Yang, Dongfeng Yan et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0313148

In recent years, the impact of professional training on brain structure has sparked extensive research interest. Research into pilots as a high-demand, high-load, and high-cost occupation holds significant academic and economic value. The aim of this study is to investigate the effects of flight training on the brain structure and cognitive functions of flying cadets. The structural magnetic resonance imaging (sMRI) data from 39 flying cadets and 37 general college students underwent analysis using voxel-based morphometry (VBM) and surface-based morphometry (SBM) methods to quantitatively detect and compute multiple indicators, including gray matter volume (GMV), curvature, mean curvature of the white matter surface (MC-WMS), the percentage of surface white matter gray matter (WM-GM percentage), surface Jacobi (S-Jacobi), and Gaussian curvature of white matter surface (GC-WMS). At the voxel level, the GMV in the left temporal pole: middle temporal gyrus region of flying cadets significantly decreased (Gaussian random field, GRF, P &lt; 0.05). At the surface level, there was a significant increase in curvature, MC-WMS, and S-Jacobi in the lateral occipital region of flight cadets (Monte Carlo block level correction, MCBLC, P&lt;0.05), a significant increase in WM-GM percentage in the cuneus region of flight cadets (MCBLC, P&lt;0.05), and a significant increase in GC-WMS in the middle temporal region of flight cadets (MCBLC, P&lt;0.05). In addition, these changes were correlated with behavioral tests. Research suggested that flight training might induce changes in certain brain regions of flying cadets, enabling them to adapt to evolving training content and environments, thereby enhancing their problem-solving and flight abilities. By analyzing multiple indicators at the voxel and surface levels in an integrated manner, it advances our understanding of brain structure, function, and plasticity, while also facilitating a more profound exploration of the neural mechanisms within the pilot’s brain.

Author Correction: Flow prediction in sound-based uroflowmetry

Scientific Reports Marcos Lazaro Alvarez, Laura Arjona, Mario Jojoa-Acosta et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89173-z

The prognostic impact of prostate-specific antigen at 6 months after post-prostatectomy radiotherapy: An individual patient data analysis of two NRG oncology randomized trials.

Journal of Clinical Oncology Osama Mohamad, David Michael Swanson, Alan Pollack et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.254

254 Background: We sought to evaluate the prognostic impact of prostate-specific antigen (PSA) within 6 months of completion of salvage radiotherapy (RT) in patients treated with RT with or without hormone therapy (HT). Methods: Individual patient data were obtained from 2 randomized trials (NRG’s RTOG 0534 and RTOG 9601) evaluating salvage RT with or without HT. HT was either androgen deprivation therapy (ADT) for 4-6 months or bicalutamide for 2 years. The lowest PSA recorded within 6 months after RT completion was identified and categorized as ≤ or &gt;0.1 ng/mL. The primary outcomes were metastasis-free survival (MFS) and overall survival (OS). Multivariable Cox proportional hazards regression was used to estimate hazard ratio (HR) with 95% confidence intervals to characterize the association of PSA within 6 months post-RT completion with OS and MFS while adjusting for age, Gleason score, trial, and HT use. Five-year MFS and 10-year OS rates were estimated using the Kaplan-Meier method. Results: Among a total of 2,373 patients, 1833 (77%) patients achieved a nadir PSA ≤0.1 and 540 (23%) did not. Among patients who did not get HT, 50% did not reach the milestone compared to only 6% of patients who got HT. PSA ≤0.1 ng/mL was associated with better OS (HR 0.27 [95% CI 0.12-0.6], p=0.001) and better MFS (HR 0.25 [95% CI 0.13-0.47], p&lt;0.0001). The interaction test showed that the improved OS/MFS in patients who achieved the nadir was more prominent in those who did not receive HT compared to those who received HT. Five-year MFS rates among patients allocated to RT, RT+ADT, and RT+ bicalutamide were 94% vs 81%, 92% vs 87%, and 91% vs 93%, respectively, based on PSA ≤ vs &gt;0.1. Ten-year OS rates among patients allocated to RT, RT+ADT, and RT+ bicalutamide were 87% vs 76%, 84% vs 84%, and 82% vs 83%, respectively, based on PSA ≤ vs &gt;0.1. Conclusions: PSA &gt;0.1 ng/mL within 6 months was prognostic for OS and MFS in patients treated with salvage RT in the post-prostatectomy setting. This finding allows better patient counseling and can guide clinical trial design for treatment intensification or de-intensification in patients receiving salvage RT.

Molecular insights of low-PSA–expressing high-risk prostate cancer.

Journal of Clinical Oncology Goutam Chakraborty, Nabila Zaman, Adriana M Pedraza et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.416

416 Background: Despite advances in molecular genetics and genome sequencing, identifying lethal and non-lethal forms of prostate cancer in the early stages of the disease remains challenging. A significant number of prostate cancer patients have high-risk tumors that produce low levels of prostate-specific antigen (PSA) at the time of diagnosis. There is an indication that the therapeutic outcome of these patients, may be considered unfavorable as they may not respond as well to ADT or androgen receptor pathway inhibitors (ARPI). Consequently, this type of high-risk prostate cancer with low PSA secretion may be associated with a unique subtype of the disease that has not been fully characterized. Methods: From 2013 to 2023, 3,619 patients diagnosed with prostate cancer underwent robotic-assisted radical prostatectomy (RARP) performed by a single experienced surgeon (AKT). The patients were classified into four groups based on their PSA levels: very low (&lt;2.5 ng/ml), low (2.6-5.0 ng/ml), medium (5.1-8.0 ng/ml), and high (&gt;8.0 ng/ml). We conducted an ANOVA analysis to compare various clinical characteristics across these groups. Additionally, we explored the gene expression profiles from the Cancer Genome Atlas (TCGA) prostate cancer cohort, specifically examining differential PSA/KLK3 mRNA expression within cancer cells. Furthermore, we selected and expanded single-cell clones from the LNCaP parental population to investigate the molecular landscape of low PSA expressing prostate tumor cells. Results: We observed that patients with high-risk prostate cancer and a very low PSA level (&lt;2.5 ng/ml) had higher rates of biochemical recurrence compared to those with high-grade cancer but PSA levels (&gt;2.5 ng/ml). Additionally, we noticed a significantly high presence of seminal vesicle (p= 1.058e-05) and neurovascular invasion (p=0.0047) in both the very low and high PSA groups compared to the other two groups. Importantly, the very low PSA group exhibited a higher rate of lymph node invasion (p= 0.00095) compared to the other three groups. Our transcriptomic analysis in the TCGA cohort revealed that genes which are upregulated in the very low PSA group compared to the high PSA group are significantly (p&lt;0.001) enriched in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, our study on LNCaP-derived clones revealed an increased migration potential and elevated expression of mesenchymal markers in LNCaP-PSA Low clones compared to the clones expressing high PSA. Conclusions: Our research identifies a distinct subtype of localized prostate cancer, demonstrating that low-PSA, high-risk prostate cancer is significantly invasive and leads to potentially lethal disease. This highlights the need for further investigation to better understand the biology of this poorly defined but aggressive subtype of localized prostate cancer.